DFO
TXG icon

Duquesne Family Office’s 10x Genomics TXG Stock Holding History

Duquesne Family Office’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.5M Buy
+403,100
New +$10.6M 0.3% 65
2022
Q4 		– Sell
-116,715
Closed -$3.32M – 79
2022
Q3 		$3.32M Buy
+116,715
New +$4.45M 0.19% 53

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Duquesne Family Office's TXG Position: Q2 2026 in Review

Duquesne Family Office opened a new position in 10x Genomics (TXG) in Q2 2026: 403,100 shares worth $15.5M. The stake represents 0.3% of the portfolio and ranks #65 among its holdings. This is a return to the name: Duquesne Family Office previously reported a position in TXG as recently as Q3 2022.

Duquesne Family Office first reported a position in TXG in Q3 2022 and has held it in 2 quarters since. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Duquesne Family Office held 403,100 shares of 10x Genomics worth $15.5M as of Q2 2026.
  • 10x Genomics was a new Duquesne Family Office position in Q2 2026.
  • 10x Genomics made up 0.3% of Duquesne Family Office's portfolio in Q2 2026, its #65 holding.
  • Duquesne Family Office first reported a position in 10x Genomics in Q3 2022 and has held it in 2 quarters since.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Duquesne Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.